Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q3 2024 Earnings Presentation
18 slides from Hansa Biopharma Ab's earnings presentation, Oct 17, 2024
Slide 1: Interim Results Conference Call
Interim Results Conference Call October 17, 2024
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Interim Results Conference Call Agenda
Interim Results Conference Call Agenda 17 October 2024 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Søren Tulstrup Chief Executive Officer, President Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A and
Slide 4: Highest ever quarterly IDEFIRIX sales performance
Highest ever quarterly IDEFIRIX sales performance Q3 Sales: 69.5 MSEK Trailing 12 Month Performance Highlights Sales Performance Product Sales Q3’24 Sales - IDEFIRIX Q/Q > 69.5 MSEK MSEK > Net Provision: 39.8 MSEK 69.5 YTD Revenue - IDEFIRIX > 164.1 MSEK 47.4 47.1 43.3 > Net Provision: 114.5 MSEK Q3
Slide 5: Significant scientific advancement in 2024
Significant scientific advancement in 2024 ConfIdeS Ph 3 PAES Ph 3 GOOD-IDES-02 Ph 3 (kidney transplant) (kidney transplant) (anti-GBM) Key Trial Progress Enrolment complete 78% enrolled 86% enrolled data read out 2H 2025 data read out 2025 data read out 2025 17-HMedIdes-14 16-HMedIdes-12 Ph 2 RWE D
Slide 6: IDEFIRIX EU launch continues to advance
IDEFIRIX EU launch continues to advance Clinical Patient Selection Market Readiness & Treatment Access 113 clinics are IDEFIRIX ready 123 local scientific events and Reimbursement in 15 markets to treat KOL engagement incl largest EU markets 32 centers with clinical experience 10% increase from Q2 7
Slide 7: Interim Results Conference
Interim Results Conference 17 October 2024 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Søren Tulstrup Chief Executive Officer, President Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A and Close Søren
Slide 8: Broad pipeline in autoimmune, gene therapy and transplantation
Broad pipeline in autoimmune, gene therapy and transplantation Marketing Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Sta tus Next anticipate d milestone authoriza tion Imlifidase EU: Kid ney transplan tation in highly Commercialization ongoing EU: Additional agreements around sensitized pat
Slide 9: Advancing the science in autoimmune, gene therapy, and transplantation
Advancing the science in autoimmune, gene therapy, and transplantation TRANSPLANT AUTOIMMUNE TRANSPLANTATION Delivering the Pipeline 15-HMedIdeS-09 Ph 2 (GBS) US ConfIdeS Ph 3 (kidney) Trial Complete Enrolment Completed 7 Ongoing clinical trials in autoimmune, Addt’l Data Readout Q4 2024 Data Readou
Slide 10: HNSA-5487 has the potential to address high unmet medical need in IgG mediated diseases
HNSA-5487 has the potential to address high unmet medical need in IgG mediated diseases HNSA-5487 ✓ Clear redosing potential with optimized IgG reduction IgG-mediated neuro-autoimmune diseases ✓ Demonstrated rapid, robust reduction of IgG by 95% after single dose 200k-300k prevalent patients ✓ Favor
Slide 11: Interim Results Conference
Interim Results Conference 17 October 2024 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Søren Tulstrup Chief Executive Officer, President Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A and Close Søren
Slide 12: Highest ever quarterly IDEFIRIX sales totalling 69.5 MSEK offset by 29.7 MSEK provision
Highest ever quarterly IDEFIRIX sales performance totalling 69.5 MSEK offset by 29.7 MSEK provision Revenue (Q/Q) Product Sales (Q/Q) Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 69.5 Product sales 78.4 (excl. provision) 29.7 29.7 Product sales MSEK (excl. provision) 47.4 47.1 56.0 MS
Slide 13: Continued investments in R&D and commercialization
Continued investments in R&D and commercialization SG&A expenses (Q/Q) R&D expenses (Q/Q) Operating loss (Q/Q) Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 -117 -76 -80 -176 -159 -91 -88 -96 -92 -187 MSEK MSEK MSEK -112 -106 -108 -103 -202 SG&A expenses (
Slide 14: Cash runway into 2026 through directed share issue in Q2'24
Cash runway into 2026 through directed share issue in Q2’24 Operating cash flow (Q/Q) Cash & Cash Equivalents (Q/Q) Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 908 732 MSEK 705 MSEK -149 541 554 -173 -193 -189 -189 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Operating cash flow (9M/9M) Number of employees (Q/Q) 2022 2023 2024
Slide 15: Interim Results Conference
Interim Results Conference 17 October 2024 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Matt Shaulis Chief Commercial Officer Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A and Close Søren Tulstrup Ch
Slide 16: Hansa Biopharma Leadership
HANSA BIOPHARMA LEADERSHIP Søren Tulstrup Hitto Kaufmann Evan Ballantyne President & CEO Chief R&D Officer CFO © 2024 H ansa Biopharma AB
Slide 17: Hansa Biopharma contacts and key events
Hansa Biopharma contacts and key events Contacts Calendar and events Evan Ballantyne 2024 Chief Financial Officer 7 SEPT Truist Securities BioPharma Symposium, NYC Email: ir@hansabiopharma.com 19 NOV Jefferies Global Healthcare Conference, London 3 DEC Piper Sandler 36th Annual Healthcare Conference
Slide 18: HAN Sar
MZ HAN Sar BIOPHARMA